-
Discovery points to drugs that would ‘short-circuit’ deadly leukemia
St. Jude researchers have found that cells of a deadly acute myeloid leukemia can be killed by blocking production of a molecular “battery.”
-
St. Jude signs RSV vaccine agreement
Agreement with Serum Institute of India to develop a vaccine for respiratory syncytial virus, a lower respiratory tract infection in infants and children.
-
HPV vaccinations crucial for childhood cancer survivors
Health provider recommendation most important predictor of HPV vaccination of adolescent and young adult survivors of childhood cancer.
From Promise, Autumn 2017
More articles from this issue
-
Medulloblastoma: The Pieces Snap Together
St. Jude scientists discover genes suspected to cause brain tumors in children. This discovery lays the foundation to expand targeted treatments.
-
Six More Reasons to Love St. Jude
Patients and families often praise St. Jude clinical care and research. Find out why they have even more reasons to love the hospital.
-
Keeping Flu at Bay
At Delaware Bay, scientists gather crucial influenza data for research and vaccine development.
-
A Referral Clinic for Rare Endocrine Cancers
St. Jude creates a national referral clinic to advance cures for rare cancers of the endocrine system.
-
Investing in the Kids
Stocks may rise and fall, but a long-term investment in the lives of children always pays dividends.
-
St. Jude in China
St. Jude continues its 25-year quest to raise the survival rate of childhood cancer for kids in China. Find out partnerships are making this possible.
-
Opening Doors to the Future
St. Jude partner Brooks Brothers has raised more than $16 million. Read about how this doorman does his part to contribute.
-
Donors and Volunteers: The Lifeblood of St. Jude
Read a heartfelt thank you letter from Richard C. Shadyac, ALSAC president and CEO, to all St. Jude supporters and volunteers.
-
New Beginnings
A surprise proposal occurs in the hospital where one patient got a new chance at life.